- Home
- DMAC vs EGHA Comparison
DMAC vs EGHA Comparison
Compare DMAC & EGHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- EGHA
- Stock Information
- Founded
- DMAC 2000
- EGHA 2025
- Country
- DMAC United States
- EGHA United States
- Employees
- DMAC N/A
- EGHA N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- EGHA
- Sector
- DMAC Health Care
- EGHA
- Exchange
- DMAC Nasdaq
- EGHA NYSE
- Market Cap
- DMAC 260.0M
- EGHA 212.9M
- IPO Year
- DMAC N/A
- EGHA 2025
- Fundamental
- Price
- DMAC $4.76
- EGHA N/A
- Analyst Decision
- DMAC Strong Buy
- EGHA
- Analyst Count
- DMAC 4
- EGHA 0
- Target Price
- DMAC $10.75
- EGHA N/A
- AVG Volume (30 Days)
- DMAC 353.4K
- EGHA 7.3K
- Earning Date
- DMAC 08-06-2025
- EGHA 01-01-0001
- Dividend Yield
- DMAC N/A
- EGHA N/A
- EPS Growth
- DMAC N/A
- EGHA N/A
- EPS
- DMAC N/A
- EGHA N/A
- Revenue
- DMAC N/A
- EGHA N/A
- Revenue This Year
- DMAC N/A
- EGHA N/A
- Revenue Next Year
- DMAC N/A
- EGHA N/A
- P/E Ratio
- DMAC N/A
- EGHA N/A
- Revenue Growth
- DMAC N/A
- EGHA N/A
- 52 Week Low
- DMAC $3.19
- EGHA $10.02
- 52 Week High
- DMAC $6.82
- EGHA $10.25
- Technical
- Relative Strength Index (RSI)
- DMAC 64.04
- EGHA N/A
- Support Level
- DMAC $4.81
- EGHA N/A
- Resistance Level
- DMAC $5.60
- EGHA N/A
- Average True Range (ATR)
- DMAC 0.45
- EGHA 0.00
- MACD
- DMAC 0.11
- EGHA 0.00
- Stochastic Oscillator
- DMAC 67.90
- EGHA 0.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About EGHA EGH ACQUISITION CORP
EGH Acquisition Corp is a blank check company.